益肝解毒方及其拆方对非酒精性脂肪性肝炎大鼠UCP-2的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (659 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To establish the rat model of non-alcoholic steatohepatitis (NASH) by high-fat diet, and to observe the effect of Yigan Jiedu Decoction and its preparation on UCP-2 in rats with NASH. Methods According to the random number table method, 60 Wistar rats were divided into normal group, model group, whole formula group, phlegm elimination group, stasis removal group and detoxification group, 10 rats in each group were given high-fat diet for 16 weeks to replicate the NASH model. Rats in the normal group (1.575 mL/100 g normal saline), model group (1.575 ml/100 g normal saline), whole formnla group (1.730 g/100 g of traditional Chinese medicine), phlegm elimination group (1.730 g/100 g of traditional Chinese medicine), stasis removal group (1.730 g/100 g of traditional Chinese medicine), and detoxification group (1.730 g/100 g of traditional Chinese medicine) were put to death after 16 weeks of intervention, and specimens were collected. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transferase (GGT), triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and reactive oxygen species (ROS) were determined by Reitman colorimetry. UCP-2 mRNA was detected by RT-PCR. UCP-2 protein was detected by Western blot. Results NASH model of rats was successfully established. The mean values of ALT, AST, GGT, TC, TG, HDL, ROS and UCP-2 mRNA in the whole formula group and its preparation groups were significantly lower than those in the model group, while LDL was higher than that in the model group, with statistically significant differences (P ＜ 0.05). The mean values of ALT, AST, GGT, TC, TG, HDL, ROS and UCP-2 mRNA in preparation groups were higher than those in the whole formula group, with statistically significant differences (P ＜ 0.05). The levels of ALT, AST, GGT, TC, TG and HDL in the stasis removal group and the detoxification group were lower than those in the phlegm elimination group, and the differences were statistically significant (P ＜ 0.05). The LDL level of the stasis removal group was higher than that of other groups, and the difference was statistically significant (P ＜ 0.05). The results of Western blot showed that compared with normal group, the expression of UCP-2 protein in the model group was increased; compared with model group, the expression of UCP-2 protein in the whole formula was decreased; while the expression of UCP-2 protein among all preparation groups was similar. Conclusion The whole formula group has the best effect, which shows that the TCM compound is the result of the synergistic effect of its components. Yigan Jiedu Decoction can inhibit the production of ROS, reduce the high expression of UCP-2 and the levels of serum ALT, AST, GGT, TC, TG, HDL, and improve the level of LDL.

Key words： Non-alcoholic steatohepatitis Recipe compotion Yigan Jiedu Decoction Rat

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Xin1 CHEN Junyi2 LU Shihong3 ZHOU Fei1 GUO Zhaowei1 ZHUANG Minzhi1 WANG Yaping1

Cite this article:

ZHENG Xin1 CHEN Junyi2 LU Shihong3 ZHOU Fei1 GUO Zhaowei1 ZHUANG Minzhi1 WANG Yaping1. Effects of Yigan Jiedu Decoction and its preparation on UCP-2 in non-alcoholic steatohepatitis rats[J]. 中国医药导报, 2019, 16(20): 9-12,28.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I20/9

[1] 王亚平，郑昕，张志银.益肝解毒方治疗痰瘀蕴毒型非酒精性脂肪性肝炎临床观察[J].上海中医药杂志，2013，46（515）：25-27.
[2] Arab JP，Barrera F，Arrese M. The Evolving Role of Liver Biopsy in Non-alcoholic Fatty Liver Disease [J]. Ann Hepatol，2018，17（6）：899-902.
[3] 郑昕，王亚平，张志银.基于“体质可调”理论治疗非酒精性脂肪性脂肪性肝炎临床研究[J].世界中医药，2014，9（3）：308-310.
[4] Golabi P，Fazel S，Otgonsuren M，et al. Association of Parity in Patients with Chronic Liver Disease [J]. Ann Hepatol，2018，17（6）：1035-1041.
[5] Liang Q，Chen H，Xu X，et al. miR-182-5p Attenuates High-Fat -Diet-Induced Nonalcoholic Steatohepatitis in Mice [J]. Ann Hepatol，2018，18（1）：116-125.
[6] Kuftinec GN，Levy R，Kieffer DA，et al. Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center [J]. Ann Hepatol，2018，18（1）：177-186.
[7] Uzlová N，Mejzlíková N，Fraňková S，et al. Transient elastography-role in the assessment of the liver disease development [J]. Vnitr Lek，2018，64（10）：916-922.
[8] Lakhani HV，Sharma D，Dodrill MW，et al. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease [J]. Int J Med Sci，2018，15（14）：1591-1599.
[9] Aliasghari F，Izadi A，Jabbari M，et al. Are Vaspin and Omentin-1 Related to Insulin Resistance，Blood Pressure and Inflammation in NAFLD Patients? [J]. J Med Biochem，2018，37（4）：470-475.
[10] Tsuma Y，Mori J，Ota T，et al. Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway [J]. Biochem Biophys Res Commun，2019，509（1）：306-313.
[11] Nielsen J，Christensen VB，Borgwardt L，et al. Prognostic molecular markers in pediatric liver disease - Are there any? [J] Biochim Biophys Acta Mol Basis Dis，2018， 1865（3）：577-586.
[12] Patoulias D，Kalogirou M. Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease，type 2 diabetes，and cardiovascular disease [J]. Prz Gastroenterol，2018，13（4）：337-339.
[13] Yuting Y，Lifeng F，Qiwei H. Secreted modular calcium-binding protein 2 promotes high fat diet （HFD）-induced hepatic steatosis through enhancing lipid deposition，fibrosis and inflammation via targeting TGF-β1 [J]. Biochem Biophys Res Commun，2019，509（1）：48-55.
[14] Janovsky CCPS，Cesena FH，Valente VAT，et al. Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria [J]. Eur Thyroid J，2018，7（6）：302-307.
[15] Méndez-Sánchez N，Zamarripa-Dorsey F，Panduro A，et al. Current trends of liver cirrhosis in Mexico：Similitudes and differences with other world regions [J]. World J Clin Cases，2018，6（15）：922-930.
[16] Jackson K，Dressler N，Ben-Shushan RS，et al. Effects of alkaline-electrolyzed and hydrogen-rich water，in a high-fat-diet nonalcoholic fatty liver disease mouse model [J]. World J Gastroenterol，2018，24（45）：5095-5108.
[17] Wan S，Zhang L，Quan Y，et al. Resveratrol-loaded PLGA nanoparticles：enhanced stability，solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy [J]. R Soc Open Sci，2018，5（11）：181457.
[18] Pattnaik K，Bhuyan P，Singh A，et al. Biopsy Proven Fibrosis in Non-Alcoholic Fatty Liver Disease：An Analysis of Risk Factors [J]. J Clin Exp Hepatol，2018，8（4）：367-374.
[19] Pan Q，Qin T，Gao Y，et al. Hepatic mTOR-AKT2-Insig2 signaling pathway contributes to the improvement of hepatic steatosis after Roux-en-Y Gastric Bypass in mice [J]. Biochim Biophys Acta Mol Basis Dis，2018，1865（3）：525-534.
[20] Weta IW，Mahadewa TGB，Sutirtayasa WP，et al. The Comparison of Simple Anthropometric and Biochemical Parameters for Predicting Liver Steatosis in Obese Balinese Young Women [J]. Open Access Maced J Med Sci，2018，6（11）：2062-2066.